Abstract
The introduction of combination antiretroviral therapy (cART) has attracted the attention of scientists and physicians all over the world to the phenomenon known as IRD, immune restoration disease. The management of IRD depends on the correct diagnosis of the syndrome, which can be difficult to establish. The atypical presentation and unpredictable course of the disease may require individual decisions regarding a delay of cART or its interruption as well as the use of corticosteroids. Thus the frequent need for individualized management of IRD can make it difficult to obtain enough results from prospective randomized trials to establish strict recommendations. However, they should be initiated as soon as possible.
MeSH terms
-
AIDS-Related Opportunistic Infections / diagnosis
-
AIDS-Related Opportunistic Infections / drug therapy*
-
AIDS-Related Opportunistic Infections / epidemiology
-
AIDS-Related Opportunistic Infections / immunology
-
Acquired Immunodeficiency Syndrome / drug therapy
-
Acquired Immunodeficiency Syndrome / epidemiology
-
Acquired Immunodeficiency Syndrome / immunology
-
Anti-Inflammatory Agents / therapeutic use*
-
Antiretroviral Therapy, Highly Active* / adverse effects
-
CD4 Lymphocyte Count
-
Causality
-
Comorbidity
-
Diagnosis, Differential
-
HIV Infections / drug therapy*
-
HIV Infections / epidemiology
-
HIV Infections / immunology*
-
Humans
-
Recovery of Function* / drug effects
-
Recovery of Function* / immunology
-
Risk Factors
-
Systemic Inflammatory Response Syndrome / diagnosis
-
Systemic Inflammatory Response Syndrome / drug therapy
-
Systemic Inflammatory Response Syndrome / immunology
-
Systemic Inflammatory Response Syndrome / mortality